Scarica l'app Stockscreener
95.06
1.08%
1.02
Dopo l'orario di chiusura:
95.06
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$94.04
Aprire:
$93.5
Volume 24 ore:
3.10M
Relative Volume:
1.18
Capitalizzazione di mercato:
$20.76B
Reddito:
$819.56M
Utile/perdita netta:
$-1.18B
Rapporto P/E:
-16.55
EPS:
-5.7434
Flusso di cassa netto:
$-951.64M
1 W Prestazione:
-4.18%
1M Prestazione:
-21.32%
6M Prestazione:
-34.21%
1 anno Prestazione:
-40.74%
Intervallo 1D:
$93.33
$95.59
Intervallo di 1 settimana:
$93.33
$97.88
Portata 52W:
$90.39
$212.75
Insmed Inc Stock (INSM) Company Profile
Nome
Insmed Inc
Settore
Industria
Telefono
908-977-9900
Indirizzo
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Compare INSM vs VRTX, REGN, MRNA, ARGX, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
95.06 | 20.76B | 819.56M | -1.18B | -951.64M | -5.7434 |
VRTX
Vertex Pharmaceuticals Inc
|
535.17 | 135.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
819.09 | 84.33B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
202.63 | 80.90B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
875.76 | 55.07B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
382.27 | 43.24B | 5.76B | 514.49M | 1.10B | 4.4813 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-10-12 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2026-09-24 | Ripresa | Goldman | Buy |
| 2026-07-21 | Iniziato | BMO Capital Markets | Outperform |
| 2026-04-10 | Iniziato | Raymond James | Outperform |
| 2026-03-30 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2026-03-16 | Ripresa | Jefferies | Buy |
| 2026-01-28 | Iniziato | Barclays | Overweight |
| 2026-01-23 | Iniziato | Roth Capital | Buy |
| 2025-12-19 | Ripresa | Truist | Buy |
| 2025-12-04 | Iniziato | Rothschild & Co Redburn | Buy |
| 2025-10-28 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-10-20 | Iniziato | Wells Fargo | Overweight |
| 2025-08-20 | Iniziato | William Blair | Outperform |
| 2025-08-13 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | Iniziato | Jefferies | Buy |
| 2025-02-25 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-04-23 | Iniziato | Truist | Buy |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2023-11-20 | Ripresa | JP Morgan | Overweight |
| 2023-07-26 | Iniziato | Guggenheim | Buy |
| 2022-12-09 | Iniziato | Mizuho | Buy |
| 2022-12-07 | Iniziato | Barclays | Overweight |
| 2022-11-18 | Iniziato | BofA Securities | Buy |
| 2022-04-27 | Iniziato | Goldman | Buy |
| 2021-12-06 | Iniziato | JP Morgan | Overweight |
| 2021-10-19 | Ripresa | Monness Crespi & Hardt | Buy |
| 2021-10-19 | Ripresa | Morgan Stanley | Overweight |
| 2021-10-08 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2020-12-17 | Iniziato | Berenberg | Buy |
| 2020-10-12 | Ripresa | Stifel | Buy |
| 2019-09-03 | Iniziato | Goldman | Buy |
| 2019-04-09 | Reiterato | H.C. Wainwright | Buy |
| 2019-02-15 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-01-17 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-01-02 | Iniziato | Canaccord Genuity | Buy |
| 2018-08-06 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-07-23 | Iniziato | Goldman | Neutral |
| 2018-04-23 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2018-03-21 | Iniziato | Morgan Stanley | Overweight |
| 2018-01-18 | Iniziato | Credit Suisse | Neutral |
| 2017-09-05 | Reiterato | Evercore ISI | Outperform |
| 2017-08-17 | Iniziato | Evercore ISI | Outperform |
| 2017-07-11 | Iniziato | Robert W. Baird | Outperform |
| 2016-03-15 | Iniziato | Stifel | Buy |
| 2015-11-09 | Downgrade | UBS | Buy → Neutral |
| 2015-10-06 | Reiterato | H.C. Wainwright | Buy |
| 2015-06-09 | Iniziato | Citigroup | Neutral |
| 2014-03-26 | Reiterato | HC Wainwright | Buy |
Mostra tutto
Insmed Inc Borsa (INSM) Ultime notizie
The Escalator: CSL, Insmed, Amgen and more - Medical Marketing and Media
Insmed names former Sanofi and Novartis CEO Hudson and biopharma exec Koppikar to board - ROI-NJ
Insmed (INSM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Zacks Investment Research
Insmed (INSM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Yahoo Finance
Form 4 Insmed Inc: Paul Hudson (Director) For: 19 October By Investing.com - Investing.com Canada
Utpal Koppikar Appointed to Insmed Board, Reports No Ownership of Company Securities - Kalkine Media
Insmed Appoints Two New Directors to Its Board - Insmed Incorporated Investor Relations
Insmed adds two directors with pharma leadership experience - Investing.com
Insmed appoints Paul Hudson and Utpal Koppikar to its Board - TradingView
Insmed adds two independent directors with biopharma backgrounds - StreetInsider
Oral Lung-Disease Tablets: Insmed Brings BRINSUPRI to Japan for NCFB - Trend Hunter
Insmed launches bronchiectasis treatment in Japan By Investing.com - Investing.com Canada
Insmed Launches BRINSUPRI® Tablets 25 mg (brensocatib hydrate) for the Treatment of Non-Cystic Fibrosis Bronchiectasis in Japan - Yahoo Finance
Insmed IncorporatedLaunches Four Pivotal Phase 3 Studies For TPIP In Pulmonary Diseases - TradingView
Insmed launches four phase 3 trials for lung disease therapy By Investing.com - Investing.com Canada
Three trials have started for Insmed's inhaled treatment; a fourth is expected in the first half of 2027. - Stock Titan
Insmed Incorporated (INSM) Options Chain - Yahoo! Finance Canada
Three presentations will examine an inhaled treatment being studied for high blood pressure in the lungs. - Stock Titan
A Quick Look at Today's Ratings for Insmed(INSM.US), With a Forecast Between $169 to $220 - Moomoo
Analysts Offer Insights on Healthcare Companies: Pfizer (PFE), ACADIA Pharmaceuticals (ACAD) and Insmed (INSM) - The Globe and Mail
Insmed Shares Fall After Wolfe Research Downgrade - Yahoo Finance
Wolfe Research Downgrades Insmed to Peer Perform From Outperform - Moomoo
Truist previews biotech earnings with focus on Insmed, BridgeBio By Investing.com - Investing.com Canada
This Insmed Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday - Benzinga
This Insmed Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday - Benzinga
BofA cuts Insmed stock price target on valuation concerns By Investing.com - Investing.com India
Weekly Recap: ARIKAYCE sNDA Jan 28, 2027 FDA date and CFO Bonstein exit - TradingView
Wolfe Research Downgrades Insmed to Peer Perform From Outperform - Yahoo Finance
US High Growth Tech Stocks Spotlight Featuring 3 Top Picks - Simply Wall Street
UBS reiterates Insmed stock rating on Brinsupri sales outlook - Investing.com
Does Insmed (INSM) CFO Exit With Reaffirmed Guidance Clarify Or Complicate Its Growth Narrative? - Yahoo Finance
INSM Stock Slides on CFO Exit, Reiterates '26 Sales View - Zacks Investment Research
INSM Stock Slides on CFO Exit, Reiterates '26 Sales View - TradingView
Bonstein to step down as Insmed chief financial officer - ROI-NJ
$100 Invested In Insmed 5 Years Ago Would Be Worth This Much Today - Benzinga
Insmed Announces CFO Transition - Insmed Incorporated Investor Relations
Insmed stock falls as CFO Sara Bonstein to step down - Investing.com
Why is Insmed stock sliding today? By Investing.com - Investing.com India
Insmed Stock Slides — CFO Exit Date Set, 2026 Guidance Reaffirmed - Benzinga
Insmed stock falls as CFO Sara Bonstein to step down - Yahoo Finance
Insmed drops as investors weigh CFO departure despite reaffirmed 2026 outlook - Quiver Quantitative
Insmed Incorporated Announces Sara Bonstein Steps Down as Chief Financial Officer, Effective October 30, 2026 - marketscreener.com
Insmed Incorporated Reaffirms Earnings Guidance for the Full-Year 2026 - marketscreener.com
Insmed Q2 2026 Earnings Call Transcript - Benzinga
Insmed CFO Sara Bonstein to step down, reaffirms guidance - TradingView
Insmed CFO Sara Bonstein to step down on October 30 By Investing.com - Investing.com Canada
Insmed CFO Sara Bonstein to step down Oct 30; c... - pluang.com
Insmed CFO Sara Bonstein to Separate, Search Underway for Successor - TradingView
Insmed (INSM) Announces CFO Transition - TradingView
Insmed Announces CFO Transition - Yahoo Finance
Insmed Inc Azioni (INSM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Insmed Inc Azioni (INSM) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Brennan David R | Director |
Sep 09 '26 |
Proposed Sale |
123.99 |
25,000 |
3,099,729 |
0 |
| SHAROKY MELVIN MD | Director |
Aug 17 '26 |
Sale |
127.53 |
5,000 |
637,650 |
0 |
| MELVIN SHAROKY | Director |
Aug 17 '26 |
Proposed Sale |
127.53 |
5,000 |
637,637 |
0 |
| Roger Adsett | Officer |
Aug 10 '26 |
Proposed Sale |
133.26 |
239,850 |
31,963,198 |
0 |
| Adsett Roger | Chief Operating Officer |
Aug 10 '26 |
Option Exercise |
20.45 |
239,850 |
4,905,570 |
338,594 |
| Adsett Roger | Chief Operating Officer |
Aug 10 '26 |
Sale |
133.27 |
239,850 |
31,964,810 |
98,744 |
| Martina Flammer | Officer |
Aug 06 '26 |
Proposed Sale |
128.61 |
27,173 |
3,494,755 |
0 |
| Flammer Martina M.D. | Chief Medical Officer |
Aug 06 '26 |
Option Exercise |
21.20 |
27,173 |
576,126 |
87,659 |
| Flammer Martina M.D. | Chief Medical Officer |
Aug 06 '26 |
Sale |
128.61 |
27,173 |
3,494,838 |
60,486 |
| Lewis William | Chair and CEO |
Jul 23 '26 |
Sale |
106.06 |
10,700 |
1,134,890 |
259,058 |
1.77%
3.08%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):